Tel. : 01 45 33 67 17 / E-mail : coger@coger.fr
AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
Ajouter au panier
Le produit a été ajouté au panier Le stock est insuffisant. unités ont été rajoutées au panier Total:
|
Stock épuisé.
En rupture de stock
|
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
|
photos non contractuelles
Product description: Chemical. CAS: 327036-89-5. Formula: C10H10N2O2S. MW: 222.3. TDZD-8 is a non-ATP competitive selective inhibitor of the serine/threonine kinase glycogen synthase kinase 3beta (GSK3beta; IC50 = 2µM), binding to the active site of GSK3beta. It does not significantly affect the activities of Cdk-1/cyclin B, CK-II, cAMP-dependent protein kinase or protein kinase C (IC50s = >100 µM), but inhibits PKC and Flt-3 activities (IC50 = 1.4-5.5µM and 673nM, respectively).TDZD-8 has been used to study the role of GSK3beta during stem cell differentiation as well as in cell and animal models of Alzheimers disease and other neurodegenerative disorders.TDZD-8 is a potent anti-proliferative and pro-apoptotic agent of glioma cells in vitro and in vivo. These effects are associated with an early activation of extracellular signal-regulated kinase (ERK), which is followed by an increased expression of the early growth response-1 (EGR-1) and p21.TDZD-8 potentially inhibits the 33.8-kDa Main protease (Mpro)/3C-like protease of SARS-CoV-2, consequently inhibiting viral transcription and replication and possibly inhibiting spread of COVID-19.
Alerte
Veuillez saisir les champs obligatoires! |